Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why
Macquarie favours Indian CDMOs, notably Divi's Labs and Suven Pharma, highlighting their superior scale and customer ...
cnbctv181d
Trump's tariff threat takes the wind out of India's pharma stocks
India currently imposes a 10% tariff on medicines imported from US. If Donald Trump decides to increase the tariff on Indian ...